The Japanese Pharmaceutical Industry - Maki Umemura

The Japanese Pharmaceutical Industry

Its Evolution and Current Challenges

(Autor)

Buch | Softcover
190 Seiten
2018
Routledge (Verlag)
978-1-138-48143-5 (ISBN)
54,85 inkl. MwSt
Charting the development of the industry from post-war devastation, through good recovery in the 1960s, and then up to the present, the book explores why Japan, despite being a world leader in many high technology industries, is only a minor player in the global pharmaceutical industry.
This book explores why Japan, despite being a world leader in many high technology industries such as automobiles and consumer electronics, is only a minor player in the global pharmaceutical industry. Japan provides a huge market for pharmaceuticals as the second largest consumer of prescription drugs after the United States, and is a massive importer of prescription drugs, relying on discoveries made elsewhere. This book charts the development of the industry, from the devastation resulting from the Second World War to its performance in the present day. Focusing in particular on antibiotics and anticancer drugs, the book analyses factors that have prevented Japan from leading the rapid advances in science and technology that have occurred globally over recent decades. Looking at the pharmaceutical industry, the book argues that the Japanese government’s research and development policies were not sufficiently incentivising. It also shows how the nature of capitalism in Japan - which featured close relations between government and industry as well as between and within firms - was appropriate for nurturing industrial development in the immediate post-war decades, but became much less effective in later years.

Maki Umemura is a lecturer in Japanese studies at Cardiff Business School, Cardiff University, UK.

1. Introduction: Why didn’t Japan become a global leader in pharmaceuticals? 2. A historical overview of Japan’s pharmaceutical industry 3. Developing a modern industry: The antibiotics sector 4. What went wrong? The anticancer drug sector 5. Conclusion: Reconsidering Japan’s business in pharmaceuticals

Erscheinungsdatum
Reihe/Serie Routledge Studies in the Growth Economies of Asia
Zusatzinfo 7 Tables, black and white; 18 Line drawings, black and white; 18 Illustrations, black and white
Verlagsort London
Sprache englisch
Maße 156 x 234 mm
Gewicht 453 g
Themenwelt Medizin / Pharmazie Pharmazie
Naturwissenschaften Biologie
Sozialwissenschaften Soziologie Spezielle Soziologien
Technik
Wirtschaft Volkswirtschaftslehre
ISBN-10 1-138-48143-2 / 1138481432
ISBN-13 978-1-138-48143-5 / 9781138481435
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Heide Lutosch

Buch | Softcover (2023)
Matthes & Seitz Berlin (Verlag)
12,00
die Unterrepräsentation von Ostdeutschen und Menschen mit …

von Raj Kollmorgen; Lars Vogel; Sabrina Zajak

Buch | Softcover (2024)
Springer Fachmedien (Verlag)
64,99